ELISpot and Fluorospot Assay Market Set to Reach USD 528.30 Million by 2032, Driven by Immuno-Oncology Research and Diagnostic Innovation

SNS Insider Unveils Strategic Insights into the U.S. ELISpot and Fluorospot Assay Market's Rapid Growth—Valued at USD 79.68 Million in 2023—While the U.S. Commands Over 40% of the Global Share Amid Diagnostic Advancements in Immunology.
Austin, June 18, 2025 (GLOBE NEWSWIRE) -- ELISpot and Fluorospot Assay Market Size & Growth Analysis:
According to SNS Insider, the global ELISpot and Fluorospot Assay Market was valued at USD 290.92 million in 2023 and is projected to reach USD 528.30 million by 2032, growing at a CAGR of 6.85% during the forecast period of 2024–2032. The U.S. market alone was valued at USD 79.68 million in 2023, forecasted to climb to USD 138.33 million by 2032, with a CAGR of 6.32%.Get a Sample Report of ELISpot and Fluorospot Assay Market@ https://www.snsinsider.com/sample-request/5790
The growth trajectory is largely fueled by increasing applications in infectious disease diagnostics, cancer immunotherapy, and autoimmune disease research. As demand for highly sensitive immune response assays grows, these platforms are rapidly being adopted by hospitals, biotech firms, and academic labs.
Market Overview
The ELISpot and Fluorospot assays are gaining traction across immunological research and clinical diagnostics due to their precision in detecting immune responses. Widely utilized in vaccine development, autoimmune disease studies, and cancer immunotherapy, these assays are supported by the increasing demand for high-sensitivity diagnostics.
The U.S. remains a key contributor to market growth, benefiting from strong research funding, a highly developed healthcare infrastructure, and the presence of major industry players. Globally, market expansion is further driven by the rising incidence of chronic and infectious diseases and the growing adoption of personalized medicine. Technological advancements in assay analyzers and kits are expected to fuel additional market momentum throughout the forecast period.
Major Players Analysis Listed in this Report are:
Becton, Dickinson, and Company (BD ELISPOT Assay System, BD FluoroSpot Assay Kit)
U-CyTech biosciences (Human IFN-γ ELISPOT Kit, Monkey IL-4 FluoroSpot Kit)
Cellular Technologies Limited (CTL) (ImmunoSpot Human IFN-γ ELISPOT Kit, ImmunoSpot Human IL-2/IL-4 FluoroSpot Kit)
Mabtech AB (Human IFN-γ ELISpotPRO Kit, Human IL-2/IL-4 FluoroSpot Kit)
Abcam (Human IFN-γ ELISPOT Kit, Human IL-17A/IL-22 FluoroSpot Kit)
Oxford Immunotec (T-SPOT.TB Test, T-SPOT.COVID Test)
Bio-Techne Corporation (Human IFN-γ ELISpot Kit, Human IL-10/IL-12 FluoroSpot Kit)
Autoimmun Diagnostika GmbH (AID) (AID iSpot ELISPOT Plate Reader, AID iSpot Spectrum FluoroSpot Reader)
Lophius Biosciences GmbH (T-Track ELISPOT Kit, T-Track CMV FluoroSpot Kit)
Bio-Connect B.V. (Human TNF-α ELISPOT Kit, Human IL-5/IL-13 FluoroSpot Kit)
Thermo Fisher Scientific (Mabtech Human IFN-γ ELISpot Kit, Mabtech Human IL-2/IL-4 FluoroSpot Kit)
PerkinElmer Inc. (ATPlite Luminescence Assay System, LANCE Ultra TR-FRET Assay)
R&D Systems (Human IFN-γ ELISPOT Kit, Human IL-17/IL-22 FluoroSpot Kit)
Enzo Life Sciences (Human IFN-γ ELISPOT Kit, Human IL-4/IL-5 FluoroSpot Kit)
MilliporeSigma (Merck KGaA) (ELISpot Plate Reader System, FluoroSpot Multi-Analyte Assay Kit)
ImmunoDiagnostics Limited (Human IFN-γ ELISPOT Kit, Human IL-21/IL-22 FluoroSpot Kit)
ALPCO (Human IFN-γ ELISPOT Kit, Human IL-10/IL-12 FluoroSpot Kit)
RayBiotech Life, Inc. (Human IFN-γ ELISPOT Kit, Human IL-6/IL-8 FluoroSpot Kit)
Cell Sciences (Human IFN-γ ELISPOT Kit, Human IL-2/IL-5 FluoroSpot Kit)
ZellBio GmbH (Human IFN-γ ELISPOT Kit, Human IL-4/IL-10 FluoroSpot Kit)
ELISpot and Fluorospot Assay Market Report Scope
Report Attributes
Details
Market Size in 2023
USD 290.92 million
Market Size by 2032
USD 528.30 million
CAGR (2024–2032)
6.85%
U.S. Market 2023
USD 79.68 million
U.S. Forecast by 2032
USD 138.33 million
Base Year
2023
Forecast Period
2024–2032
Key Regional Coverage
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Segment Analysis
By Product
The assay kits segment captured the highest market share of 48.56% in 2023. This is due to the extensive use of assay kits in research and diagnostic applications. The need for high-sensitivity detection in immunological studies also contributes to the growth of this segment.
The segment of analyzers will be growing at the highest rate. The high demand for automated and high-throughput analyzers in research and laboratory settings is driving the growth of this segment. These analyzers improve accuracy and efficiency, leading to increasing demand in the market.
By Application
The diagnostic applications market held 65.41% of the market share in 2023. The growing incidence of infectious diseases, autoimmune diseases, and cancer has driven the demand for ELISpot and Fluorospot assays in clinical diagnostics. These assays provide accurate and early detection, leading to their popularity in diagnostic laboratories and healthcare facilities.
The research applications segment is expected to witness the most rapid growth. The growing emphasis on immunological research, vaccine discovery, and T-cell monitoring in cancer and infectious disease research is propelling the growth of this segment. Growing funding and advances in technology are also driving its rapid growth.
By End Use
The hospitals and clinical laboratories segment accounted for the largest share of 47.25% in 2023. The rising need for sophisticated diagnostic equipment in healthcare facilities, as well as the rising number of hospital-based research studies, has supported the application of ELISpot and Fluorospot assays in hospitals and clinical labs.
The biopharmaceutical and research institutes segment is expected to grow at the fastest rate. The growing investment in drug discovery and immunological research by academic institutions and pharmaceutical companies is fueling the demand for these assays in research settings.
For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ https://www.snsinsider.com/request-analyst/5790
ELISpot and Fluorospot Assay Market Segmentation
By Product
Assay Kits
Analyzers
Ancillary Products
By Application
Research Applications
Diagnostics Applications
By End Use
Hospital and Clinical Labs
Academic and Research Institutes
Biopharmaceutical Company
Regional Insights
North America dominated the worldwide market in 2023 with a share of 36.25%, driven by its well-developed healthcare infrastructure, robust research culture, and high prevalence of adoption of next-generation diagnostic technologies. The United States is particularly prominent because of high government and private investment in immunology and infectious disease research.
The Asia-Pacific market is expected to have the highest growth rate until 2032. The major drivers include the growth of healthcare infrastructure, higher R&D spending, and an increasing prevalence of infectious diseases.
Recent Developments
February 2025: BD announced the separation of its Biosciences and Diagnostic Solutions business to enhance strategic focus and growth, potentially impacting its immunoassay product offerings, including ELISpot and Fluorospot assays.
April 2024: U-CyTech Biosciences was recognized as a leading company in the ELISpot and Fluorospot assay market, significantly contributing to immunological research and clinical diagnostics.
February 2024: Cellular Technology Limited (CTL) was identified as a major player in the ELISpot and Fluorospot assay market, with substantial contributions to assay development and distribution.
Statistical Insights and Trends Reporting
The United States accounted for approximately 40% of the global market share in 2023, driven by extensive research funding and strong healthcare infrastructure.
The total number of ELISpot and Fluorospot assay kits and analyzers deployed worldwide is expected to increase by 70% between 2024 and 2032.
The spending on immunology-based diagnostics, including ELISpot and Fluorospot assays, increased by 9.5% in 2023, reflecting the growing focus on early disease detection.
The use of ELISpot and Fluorospot assays in immuno-oncology research is expected to grow by 85% by 2032, driven by increasing interest in personalized medicine and T-cell monitoring.
Buy a Single-User PDF of ELISpot and Fluorospot Assay Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/5790
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Immune-related Diseases (2023)
5.2 Research and Clinical Adoption Trends, by Region (2023)
5.3 Assay Kit and Analyzer Volume, by Region (2020-2032)
5.4 Assay Kit and Analyzer Volume, by Region (2020-2032)
6. Competitive Landscape
7. ELISpot and Fluorospot Assay Market by Product
8. ELISpot and Fluorospot Assay Market by Application
9. ELISpot and Fluorospot Assay Market by End Use
10. Regional Analysis
11. Company Profiles
12. Use Cases and Best Practices
13. Conclusion
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

New York Post

8 hours ago

• New York Post

Canadian tourism industry goes on offensive, as US travelers ditch Great White North

Canada's tourism industry is going on an offensive — rolling out ad campaigns in US border states to lure Americans back to the Great White North. US travel to Canada dipped by about 10% in recent months, amid the raging trade war between the two neighbors. An American tourist looks confused as he receives a warm hug from a Canadian hotel employee in a new TV ad. YouTube/Tourisme Cantons-de-l'Est Advertisement In one TV ad running across New England and New York, an American tourist – sporting a baseball cap and matching sweater tied around his shoulders – sheepishly whispers to a Canadian hotel front desk worker that he's from the land of the free. The employee looks awkwardly towards him and presses what looks like some kind of red panic button – before bursting out a smile and walking across the desk to hug him. Advertisement Other ads take more of a practical approach, trying instead to appeal to American's pocketbooks. One billboard campaign simply reminds Americans how much further their dollar will go north of the 49th parallel. '$1 USD = $1.43 CAD,' reads the billboard from Destination Ontario, which has been spotted in Detroit and Cleveland, among other border towns. 'Spend less, do more.' Americans make up more than three-quarters of tourists to Canada. Destination Ontario Advertisement American tourists make up the bulk of visitors to Canada – last summer, 78.5%, nearly four out of five visitors to the Great White North came from the US. The drop hasn't been as dramatic as Canadian tourists to the US – who've boycotted the country en masse, leading to a 30-40% fall in air and land travel. But it's sure to make a dent in the tourism industry – according to Statistics Canada, Americans spent $15.3 billion in the country last year.

Business Wire

a day ago

• Business Wire

AM Best Assigns Credit Ratings to Interplus Re Limited

BUSINESS WIRE)-- AM Best has assigned a Financial Strength Rating of B (Fair) and a Long-Term Issuer Credit Rating of 'bb+' (Fair) to Interplus Re Limited (Interplus) (Barbados). The outlook assigned to these Credit Ratings (ratings) is stable. The ratings reflect Interplus' balance sheet strength, which AM Best assesses as strong, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management. Interplus is a reinsurance company incorporated under the Laws of Barbados on Aug. 11, 2021, as a Class 2 License Insurance Company. Interplus is 98% owned by INTEHO Limited, based in Barbados. Interplus offers reinsurance products mainly focused on property business, which accounts for almost 79% of its gross written premium portfolio, followed by surety and credit lines (12%), accidents and health (8%) and the remaining (less than 1%) in life. Two thirds of the businesses underwritten by Interplus originates in Latin America and the Caribbean, with moderate concentration in Ecuador (29% of gross written premiums as of December 2024). The remaining 34% of its portfolio is distributed across Asia (25%), Africa (5%), Europe (4%) and Oceania (less than 1%). Interplus reached USD 34.9 million in gross written premiums during 2024, its third year of operation. AM Best assesses Interplus' business profile as limited due to the recent creation of the company and its small size within a highly competitive global market. Interplus' balance sheet strength is assessed as strong, reflecting the expected volatility of a startup company, its developing investment strategy and adjusting risk profile. The company's capital base has grown since its foundation, to USD 25.1 million as of December 2024, reflecting two years of positive net results and shareholder support from significant capital infusions. AM Best expects Interplus to continue strengthening its capital base through profitable results and prudent capital management. Interplus reported positive bottom-line results of USD 16 million as of December 2024. Reserve adjustments benefited technical results, allowing for a combined ratio of 32%, well within premium sufficiency levels. AM Best expects Interplus to remain profitable through adequate risk selection and stable expenses. The stable outlooks reflect AM Best's expectation that Interplus will continue strengthening its capital base, through prudent capital management and profitable results, to sustain its business plan to maintain current rating levels. Negative rating actions could take place if Interplus' operating performance deteriorates to a point no longer supportive of the adequate assessment and losses further weaken the company's balance sheet strength. Positive rating actions could take place if Interplus is able to consistently strengthen its capital through reinvestment of earnings or capital infusions, demonstrating stability at levels that support the current ratings, according to Best's Capital Adequacy Ratio (BCAR). This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.

Yahoo

a day ago

• Yahoo

Circle stock extends stunning rally amid high hopes for crypto 'disruptor'

Circle (CRCL) stock's massive rally is showing no signs of cooling. The issuer of USDC stablecoins (USDC-USD) soared roughly 15% in morning trading on Friday, extending its stunning post IPO gains as Wall Street bets big on the crypto player. "Circle as a top-tier crypto 'disruptor' with a sizeable future opportunity," Seaport Research Partners analyst Jeff Cantwell wrote in a note on Friday. He said that the company would benefit from an improving regulatory climate in the US. "We think the overall stablecoin 'market cap' will reach $500B by the end of next year; longer-term, we think it ultimately can reach $2T," he added. Cantwell initiated Circle with a Buy rating and a price target of $235. Shares hovered near $228 each during Friday's rally. The stock is on track to close out the week up more than 65%. Shares are up more than 600% above their IPO price of $31. Circle surged on Wednesday following the Senate's passage of the GENIUS Act, legislation that provides a federal framework for stablecoins, tokens backed by assets, such as the US dollar. "History is being made, as the US Senate passes the GENIUS Act, taking us one step closer to breakthrough legislation being signed into law that will drive US economic and national competitiveness for decades to come," Circle co-founder and CEO Jeremy Allaire said on X following the bill's passage. Read more about Circle's stock moves and today's market action. Circle issues the stablecoin USDC, which stands for USD coin and is backed by the dollar. The company makes most of its revenue from "reserve income," which is what it makes on cash backing its stablecoin that is held in banks or invested in Treasury bills. Momentum surrounding stablecoins also sent shares of trading platform Robinhood (HOOD) and crypto exchange platform Coinbase (COIN) higher in recent weeks. Coinbase holds a minority stake in Circle. Ines Ferre is a senior business reporter for Yahoo Finance. Follow her on X at @ines_ferre. Click here for in-depth analysis of the latest stock market news and events moving stock prices